Pure Global
NCT06313931

Effects of Cognitive-motor Training on Cognition, Depression and Daily Functioning in Patients With Mild Cognitive Impairment (MCI)

Effects of Cognitive-motor Training on Cognition, Depression and Daily Functioning in Patients With Mild Cognitive Impairment (MCI): A Randomized Controlled Trial
Universidad de Zaragoza·ClinicalTrials.gov·device·Device trialCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Mild Cognitive Impairment
Drug/Device/Intervention
cognitive training via immersive virtual reality
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Universidad de Zaragoza
Location
Teruel, Spain
Timeline & enrollment
Phase
N/A
Start date
Jul 03, 2023
End date
Sep 14, 2023
Enrollment
26 participants
Primary outcome

Spanish version of the Montreal Cognitive Assessment (MoCA-S),Short Geriatric Depression Scale (SGDS-S),Instrumental Activities of Daily Living Scale (IADL-S)

Summary

This randomized controlled trial evaluated the effectiveness of an immersive virtual reality
 (IVR) application (focused on a daily activity) to train cognitive functions and its impact
 on depression and the ability to perform activities of daily living (ADL) in patients with
 mild cognitive impairment (MCI). With a dose of two sessions per week during six weeks, the
 study showed significant improvements in cognitive functions and reduction in depression,
 with notable effects in the experimental group. This underscores the potential of IVR as a
 valuable tool in the management of MCI.

ICD-10 classifications
Mild cognitive disorderAlzheimer diseaseDementia in other specified diseases classified elsewhereDementia in other diseases classified elsewhereDementia in Alzheimer disease
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06313931
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06313931 through Pure Global AI's free database. This phase not specified trial is sponsored by Universidad de Zaragoza and is currently Completed. The study focuses on Mild Cognitive Impairment. Target enrollment is 26 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.